建立基于历史重复剂量数据的药物中间体毒理关注的门,并将其应用于设定基于健康的暴露限值
Zoe Dunn1, Delorice Murudzwa2, Kamila Blum3
1GSK, Health Hazard Assessment, Environment Health Safety (EHS), Stevenage, United Kingdom.
Regulatory toxicology and pharmacology : RTP
|December 10, 2024
概括
制药中间体 (IM) 的有限毒理数据阻碍了基于健康的暴露限值 (HBEL) 的计算. 为IMs提出的默认HBEL有助于工人和患者的安全,支持未来的数据放弃.
科学领域:
- 制药制造业 制药制造业 制药制造业
- 毒理学 毒理学 毒理学
- 职业健康 职业健康 职业健康 职业健康
背景情况:
- 有限的毒理学数据,特别是重复剂量毒性 (RDT),使得制药中间体 (IM) 的基于健康的暴露限值 (HBEL) 设定变得复杂.
- 包括职业暴露限值 (OEL) 和允许的每日暴露 (PDE) 在内的HBEL对于确保工人和患者的安全至关重要.
研究的目的:
- 分析孤立的IM的历史毒理学数据,以确定可靠的HBEL.
- 为缺乏数据的IM提出默认的HBEL,以促进安全评估.
主要方法:
- 对103个GSK隔离IM的28天口服动物毒性数据的分析.
- 提取没有观察到的 (不良) 影响水平 (NO(A) ELs) 和关键影响.
- 使用NO(A) EL和基准剂量下置信限值 (BMDL) 作为起点 (PoD) 来计算特定物质的HBEL.
主要成果:
- NO (A) EL分布的第五百分位是每天15毫克/公斤.
- 99%的IM满足了建议的默认HBEL:口服PDE≥1000μg/天和OEL≥100μg/m3.
- 默认的HBEL得到了BMDL评估的支持.
结论:
- 建议IM的默认口服PDE为1000微克/天,OEL为100微克/立方米.
- 这些默认限值可以作为毒理关注 (TTC) 的值,并有助于为新型或数据差的IM设定HBEL.
- 拟议的默认支持未来通过阅读交叉方法可能放弃研发技术要求.
关键词:
基于健康的暴露限值 (HBEL)中介产品 (IM) 是指中间产品.职业暴露限值 (OEL) 是指职业暴露的极限值.允许的每日暴露 (PDE)重复剂量毒性 (RDT) 是指重复剂量毒性.有毒性关注的门 (TTC)更多相关视频
相关概念视频
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Therapeutic Index
4.1K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.1K
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Drug Concentration Versus Time Correlation
617
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
617
Toxic Reactions: Overview
947
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
947


